TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04642235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature Nook
Description: The Nature Nook intervention will take place on lots that already have the standard greening intervention. In addition, design elements will be added such as a simple path and benches to explicitly invite people into the space. An additional difference is the exclusive use of larger, corner lots, rather than smaller mid-block spaces, to maximize visibility.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature Coach
Description: The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.~Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature Nook + Nature Coach
Description: The combined intervention will involve the installation of Nature Nooks to blighted vacant lots followed by the delivery of the Nature Coach intervention to people living in the immediate surrounding blocks. The intervention will be tailored to explicitly direct participants to use the Nature Nook.
Study: NCT05275114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS stimulation with hand task
Description: 30 minutes of intervention including tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS stimulation with hand task
Description: 30 minutes of intervention including sham tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
Study: NCT06255886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protein pump inhibitor. Continuing nutrition containing cows' milk protein.
Description: 1 mg/kg /day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother or infant diet
Description: Mother on cow milk protein diet or infant on hypoallergenic formula in case of bottle fed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medicine (appearing substantially like Omeprazole) 1mg/ ml, and continuing nutrition containing cows' milk protein
Study: NCT06657066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone 200mcg, salbutamol 100mcg , Beclomethasone 200 mcg/Formoterol 6 mcg, 250 mg of lyophilized saccharomyces boulardii
Description: Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram plus Saccharomyces boulardii, available in sachet from employed in this research containing 250 mg of lyophilized saccharomyces boulardii. It was given daily for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (Standard treatment)
Description: The control arm will receive only standard treatment for asthma i.e Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram.
Study: NCT06656897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FallScape for Persons with Alzheimer's disease or a related Dementia (FS-D)
Description: FS-D is a multimedia behavioral intervention for use by family Caregivers (CG) of Persons with Alzheimer's disease or a related dementia (PwADRD) who are living at home and classified as at moderate to high risk for falls. FS-D will create, customize and support CG-provided daily multimedia sessions for PwADRD using structured learning techniques.
Study: NCT06656351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100mg
Description: Tafenoquine
Study: NCT06657677

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40mg oral iron dosing
Description: Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100mg oral iron dosing
Description: Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 180mg oral iron dosing
Description: Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
Study: NCT05294900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin
Description: Induction chemotherapy : total 2 cycle every 3weeks as below:~* Paclitaxel 175mg/m2~* Carboplatin AUC5
Study: NCT06143631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Oral letrozole 2.5mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Oral letrozole 2.5mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT06296264

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard ultrasound
Description: Placement of IV line using standard ultrasound.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-portable ultrasound
Description: Placement of IV line using ultra-portable ultrasound.
Study: NCT04810052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Perform 1 nice thing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Write a letter or note of gratitude

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Track daily activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05895513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg
Description: 5HT-2a receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Comparator
Study: NCT04914897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Intravenous infusion: solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Intravenous infusion: solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Intravenous infusion: solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Intravenous infusion: solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion: solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion: solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion: solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion: solution for infusion
Study: NCT05091346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsule.
Study: NCT06623981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Brief Interpersonal Psychotherapy
Description: Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual sessions carried out within an 8-12-week timeframe.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supplemented Usual Care
Description: Usual care for caregivers with PHQ-9 scores 10-27 involves the asthma clinic physician discussing the PHQ-9 results with the caregiver, providing brief psychoeducation on depression and giving the caregiver a written list of mental health resources. Usual care will be supplemented by providing short-term care coordination. Care coordination will involve assisting the participant in calling a mental health clinic to make an appointment and one follow-up phone call within two weeks.
Study: NCT06443086

Intervention type: PROCEDURE
Intervention: Radical operation and perioperative therapy
Description: Surgical intervention, particularly radical excision, was performed for each patient, including the extent of resection and lymph node dissection. Information on adjuvant therapies, such as chemotherapy and radiotherapy, was also recorded, specifying the regimens and durations.
Study: NCT04664738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10% PEP
Description: PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TISSEEL
Description: Fibrin sealant made from pooled human plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% PEP
Description: PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% PEP
Description: PEP is comprised of platelet derived extracellular vesicles enriched in anti-inflammatory and angiogenic growth factors.
Study: NCT06267313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Training attention away from threat

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Training
Description: Training attention control

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral training
Description: Attention training with Neutral stimuli
Study: NCT04722458

Intervention type: OTHER
Intervention: Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29)
Description: LURN SI-29

Intervention type: OTHER
Intervention: IPSS
Description: International Prostate Symptom Score
Study: NCT04772235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be taken orally at 80 mg once daily with or without food. Part A: lead in dose in monotherapy at 80 mg QD during 14 days. In combination with repotrectinib afterwards. Depending on the safety and PK/ dose dependent interactions (DDIs) readout during the DLT assessment period, osimertinib dose may be adjusted.~Part B: at the RP2D level in combination with repotrectinib
Study: NCT04840667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REPLAGAL
Description: Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
Study: NCT05780866

Intervention type: OTHER
Group type: OTHER
Intervention: Video and Activity Tracker
Description: At enrollment, the participants will complete a baseline survey, PDQ-39 (Parkinson's disease questionnaire), and the Unified Parkinson's Disease Rating Scale (UPDRS) assessment. The researchers will provide the participant with a camera, small tripod, and a set of written directions about how to record the UPDRS motor self-assessment video.~After completing the baseline assessments, the research team will provide the participant with a Fitbit Inspire 3 activity tracker watch. The participant will wear the activity tracker for 24 hours a day for the next 14 days except for if the device needs charging and when bathing.~At 14 days, the research team will send participants a link to complete a web-based exit survey about their experience with the activity tracker during the study.
Study: NCT04722458

Intervention type: OTHER
Intervention: UDI-6
Description: Urogenital Distress Inventory
Study: NCT05426265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEL-T01
Description: A 12 week intervention with MEL-T01.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEL-S01
Description: A 12 week intervention with MEL-S01.
Study: NCT06483789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-1
Description: HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan Only Product in Oral Dose Form
Description: Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Only Product in Oral Dose Form
Description: Verapamil will be supplied as a single active pharmaceutical ingredient tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo will be supplied as a tablet.
Study: NCT05934825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable suspension of allogeneic adult mesenchymal stem cells
Description: Cell therapy treatment will be administered in a single dose at the beginning of the study. The treatment consists of the administration of a single dose of allogeneic adult mesenchymal stem cells from adipose tissue. The dose is 120 million cells (drug volume: 20 ml, concentrated at 6 million cels/ml).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of the administration of the excipient of the suspension without cells. The excipient is a mixture of 50% hyaluronic acid, 49% DMEM without phenol red and 1% L-Alanine-L Glutamine.
Study: NCT04710758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic total gastrectomy
Description: LTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open total gastrectomy
Description: OTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
Study: NCT06485700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Delivery of Medications
Description: Door-to-door peer delivery of medications within patients' communities will be implemented.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Information Technology (HIT) Platform
Description: The HIT platform provides: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) medication refill tracking to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data.
Study: NCT05490888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHIN-214 Subcutaneous injection
Description: subcutaneous injection(s) with PHIN-214 terlipressin derivative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHIN-214 Subcutaneous injection
Description: subcutaneous injection(s) with PHIN-214 terlipressin derivative
Study: NCT05819918

Intervention type: DRUG
Intervention: Calcifediol
Description: Subjects hospitalized with COVID-19 treated with calcifediol

Intervention type: DRUG
Intervention: Best available therapy
Description: Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.
Study: NCT05125211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001 recombinant peptide spray
Description: administrated oral spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001 recombinant peptide spray
Description: administrated oral spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001 recombinant peptide spray
Description: administrated oral spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administrated oral spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administrated oral spray
Study: NCT06560762

Intervention type: DRUG
Group type: OTHER
Intervention: STM01
Description: Neonatal mesenchymal stem cells (nMSCs),
Study: NCT04845802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training(high-IMT group)
Description: A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training. Training intensity will set at 60% of the maximum inspiratory pressure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training(low-IMT group)
Description: Dancers will be perform at a load setting of level 1 (corresponding to \~10% baseline MIP), using the same device as the training group.
Study: NCT04243538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-HoME
Description: I-HoME will consist of two components: (1) synchronous live video interactions between patients/CGs and a hospice nurse; and (2) educational videos.
Study: NCT06560346

Intervention type: OTHER
Intervention: Geneticlly confirmed disease causing FXN mutatuion
Description: No intervention in this observational Natural History Study

Intervention type: OTHER
Intervention: Healthy Control
Description: No intervention in this observational Natural History Study
Study: NCT06419205

Intervention type: DRUG
Group type: OTHER
Intervention: ADX-097
Description: Open Label
Study: NCT05449743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
Study: NCT04889716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mosunetuzumab
Description: 1 mg IV on Cycle 1 Day 1; 2 mg IV Cycle 1 Day 8; 60 mg IV Cycle 1 Day 15; 60 mg IV on Cycle 2 Day 1 and then 30 mg IV every 21 days beginning Cycle 2 Day 1 through Cycle 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glofitamab
Description: 2.5 mg IV Cycle 1 Day 8; 10 mg IV Cycle 1 Day 15 then 30 mg every 21 days beginning Cycle 2 Day 1 through Cycle 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg IV on Cycle 1 Day 1.
Study: NCT04723134

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid calcium salt
Description: Folinic acid (2.5%) by combination with Placebo

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Folinic acid calcium salt
Description: Folinic acid (2.5%) by combination with Placebo
Study: NCT05719493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multicomponent treatment
Description: The intervention to be evaluated consists of 4 group sessions carried out in two weeks, 6 hours per week divided in 2 days (a total of 12 hours), of active education in nutrition, chronobiology and physical exercise in people diagnosed with Chronic Fatigue Syndrome and Fibromyalgia.
Study: NCT06130345

Intervention type: BIOLOGICAL
Intervention: SPIKEVAX
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Intervention: SPIKEVAX
Description: Intramuscular injection
Study: NCT05842473

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (active)
Description: Theta-burst transcranial magnetic stimulation (active) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Language therapy
Description: Language therapy immediately after each TMS session. Daily sessions for two weeks followed by 1 session per week.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Language therapy
Description: Language therapy immediately after each TMS session. Daily sessions for two weeks followed by 1 session per week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (sham)
Description: Theta-burst transcranial magnetic stimulation (sham) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
Study: NCT04777994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-484
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-484
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-484
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-484
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-484
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-484
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed Cell Death-1 (PD-1) Inhibitor
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed Cell Death-1 (PD-1) Inhibitor
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
Description: Oral Tablet